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Abstract
Background: Scale up of paediatric antiretroviral therapy in resource limited settings continues despite limited
access to routine laboratory monitoring. We documented the weight and height responses in HIV infected
Ugandan children on highly active antiretroviral therapy and determined clinical factors associated with successful
treatment outcomes.
Methods: A prospective cohort of HIV infected children were initiated on HAART and followed for 48 weeks. Body
mass index for age z scores(BAZ), weight and height-for-age z scores (WAZ & HAZ) were calculated: CD4 cell %
and HIV-1 RNA were measured at baseline and every 12 weeks. Treatment outcomes were classified according to;
both virological and immunological success (VS/IS), virological failure and immunological success (VF/IS). virological
success and immunological failure (VS/IF) and both virological and immunological failure (VF/IF).
Results: From March 2004 until May 2006, 124 HIV infected children were initiated on HAART. The median age
(IQR) was 5.0 years (2.1 - 7.0) and 49% (61/124) were female. The median [95% confidence interval (CI)] BAZ, WAZ
and HAZ at baseline were 0.29 (-2.9, -1.2), -1.2 (-2.1, -0.5) and -2.06 (-2.9, -1.2) respectively. Baseline median CD4 cell
% and log10 HIV-1 RNA were; 11.8% (7.5-18.0) and 5.6 (5.2-5.8) copies/ml. By 48 weeks, mean WAZ and HAZ in the
VF/IS group, which was younger, increased from - 0.98 (SD 1.7) to + 1.22 (SD 1.2) and from -1.99 (1.7) to + 0.76
(2.4) respectively. Mean increase in WAZ and HAZ in the VS/IF group, an older group was modest, from -1.84 (1.3)
to - 0.41 (1.2) and -2.25 (1.2) to -1.16 (1.3) respectively. Baseline CD4 cell % [OR 6.97 95% CI (2.6 -18.6)], age [OR 4.6
95% CI (1.14 -19.1)] and WHO clinical stage [OR 3.5 95%CI (1.05 -12.7)] were associated with successful treatment
outcome.
Conclusions: HIV infected Ugandan children demonstrated a robust increase in height and weight z scores during
the first 48 weeks of HAART, including those who failed to completely suppress virus. Older children initiating
HAART with severe immune suppression were less likely to achieve a successful treatment outcome. These data
emphasize the importance of initiating HAART early to ensure adequate immune and growth responses.
Background
Growth failure is a well recognized complication of HIV
infection in children which can present as stunting,
weight loss, failure to thrive and severe acute malnutri-
tion which respond poorly to nutritional rehabilitation
[1-3]. The mechanism for this growth failure is complex
and multifactorial, including inadequate caloric intake,
gastrointestinal infestations, opportunistic infections and
HIV enteropathy [4,5]. Abnormal resting energy expen-
diture and endocrine abnormalities may also contribute
to the diminished growth noted in perinatally HIV
infected children [6]. In Africa, HIV related nutritional
deficiencies compound the already high back-ground
rates of malnutrition found in young children [7]. In
Uganda, 39% and 16% of all children under five years of
age are stunted and underweight respectively [8].
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any medium, provided the original work is properly cited.Although there is a high prevalance of growth failure in
HIV infected children from sub-Saharan Africa, recent
studies have reported a growth response among children
initiated on highly active antiretroviral therapy
(HAART), including significant weight gain and increase
in height after some delay [9-11].
HAART has become more widely available for chil-
dren from resource-limited settings. The monitoring of
antiretroviral treatment response in children and adults
from sub-Saharan Africa remains mainly clinical with
limited access to immunological and virological tests,
except in the larger cities [12]. Therefore it is critical to
demonstrate that basic growth parameters, which can be
measured by primary level health care workers in
resource limited settings, are associated with successful
HIV treatment outcomes. Sustained increase in height
and weight in children on HAART have been linked to
successful virological response [13]. The objective of this
study was to document the growth response to HAART
in a cohort of HIV infected Ugandan children and to
determine clinical factors including growth parameters
associated with successful virologic and immunologic
treatment outcome.
Methods
The study design and methods for this cohort of HIV
infected children initiating HAART in Makerere Univer-
sity-Johns Hopkins University Collaboration (MU-JHU
Care Ltd) HIV Care Clinic are reported elsewhere [14].
In summary, we conducted a prospective cohort study
of HIV infected Ugandan children initiated on highly
active antiretroviral therapy (HAART) between March
2004 and May 2006. Response to HAART was moni-
tored using clinical measurements including height and
weight; and laboratory parameters including CD4 cell
counts/percents and HIV-1 RNA. The study was
approved by the Makerere University Research and
Ethics Committee and the Uganda National Council for
Science and Technology. Informed consent was obtained
from parents/guardians before study specific procedures
were performed.
Study population
A total of 130 HIV-infected children who were eligible
for antiretroviral therapy (ART) were enrolled into the
ART program at Makerere University-Johns Hopkins
University Research Collaboration (MU-JHU) Kampala,
Uganda. HIV infected children between 6 months and
12 years of age were initiated on HAART using the
2003 WHO criteria for antiretroviral therapy in
resource-limited settings [15]. For this analysis, 124 chil-
dren had growth measurements available and 123 com-
pleted the 48 weeks of follow up. Seven children died
during the study follow up but one of them died after
44 weeks of follow up and therefore had data for most
of the study time points except for week 48.
All the children received a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI)-based adult fixed dose com-
bination (FDC) antiretroviral drug Triomune (CIPLA,
India), containing stavudine (d4T 30 or 40 mg), lamivu-
dine (3TC 150 mg) and nevirapine (NVP 200 mg). Those
children who weighed less than 10 kg at HAART initia-
tion, were prescribed syrup formulations of the same
antiretroviral drugs until they weighed > 10 kg, when
they were switched to Triomune. The triomune tablet
was dosed based on the weight of the child and the indi-
vidual antiretroviral (ARV) dosage was estimated accord-
ing to weight band dosing [16]. Therefore the children
received 1/4, 1/2 or 1 tablet of Triomune depending on
their weight band. Children who developed a rash due to
NVP hypersensitivity (n = 2) had their Triomune discon-
tinued and they were switched to an alternative regimen,
d4T + 3TC + efavirenz (EFV). None of the children were
switched to second line antiretroviral therapy during the
48 weeks of follow up.
Procedures
Study visits were conducted at baseline and every week
for the first month, every two weeks for the second
month and then every four weeks until 48 weeks. At the
routine follow-up visits, anthropometric measurements
were recorded, a physical exam was performed as was
clinical staging, based on the 2003 WHO staging for
infants and children. At baseline and every 12 weeks,
blood was collected for CD4 cell counts/percents and
plasma HIV-1 RNA. Children also received follow up
clinical care which included multivitamins, cotrimoxa-
zole prophylaxis, and free medication for all acute ill-
nesses. Caregivers and children, if age appropriate,
received adherence counseling at each scheduled follow-
up visit. Adherence monitoring was conducted at each
follow-up visit and was based on pill counts and self-
reports from caregivers. Caregivers were provided with a
30 day supply of the antiretroviral medication.
Measurements
Growth measurements
Heights and weights were recorded for each child at
each routine follow-up visit. This was done by staff
trained in carrying out accurate measurements; and
standardized stadiometers and scales were used. The
body mass index (BMI) was calculated from height and
weight measures as defined by BMI equal to weight
(kilograms)/height (meter
2). Median weight-for-age z
score (WAZ), median height-for-age z score (HAZ) and
body mass index-for-age z score (BAZ) were calculated
using the WHO-child growth standards [17]. A z score
of 0 represents the p50 which is the median age/sex
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cates that the child’s weight or height is 1 standard
deviation (SD) below the median weight or height for
the reference population.
Laboratory measurements
Participants had blood drawn at baseline for measure-
ment of complete blood cell count (CBC), CD4 cell
count/percent, liver transaminases, renal function tests
(creatinine) and plasma HIV-1 RNA. Repeat CD4 cell
counts/percents and plasma HIV-1 RNA levels were
done at 12, 24, 36 and 48 weeks after HAART initiation.
All laboratory tests were performed at the MU-JHU
Core Lab, Kampala Uganda, which is certified by the
College of American Pathologists. The CD4 cell counts/
percents were assessed by BD FACS Calibur instrument
(Becton, Dickinson & Company). Plasma HIV RNA
levels were measured using the Amplicor HIV-1 Moni-
tor Test, version 1.5 Standard assay (Roche Company,
Branchburg, New Jersey/USA). Plasma HIV-1 RNA
levels >750,000 copies/ml were diluted and further
assessed by dilution.
Laboratory based Definitions of Treatment Success
used in this analyses: HIV-1 RNA levels that were <400
copies/ml were considered undetectable and a successful
treatment outcome for the purpose of these analyses.
Virological treatment success (VS) was defined as unde-
tectable viral load (< 400 copies/ml) after 24 weeks of
HAART and sustained through 48 weeks of follow up.
Immunological treatment success (IS) was defined as
achievement of a CD4 cell percent above the age cut off
level for severe immunosuppression (CD4 cell percent;
less than one year > 25%, one to five years > 20%,
greater than five years > 15%) after 24 weeks of HAART
and sustained throughout the follow up period.
Statistical analysis
Descriptive statistics are presented as medians with
inter-quartile ranges (IQR) and means with standard
deviations (SD). Proportions of different baseline charac-
teristics of study children and their respective 95% con-
fidence intervals (CIs) are also provided. Chi square test
p-values were used to compare baseline categorical vari-
ables. Kruskal Wallis p-values were used to compare
medians of continuous variables at baseline. The pri-
mary endpoint for this analysis was achievement of a
viral load less than 400 copies/ml at 24 weeks sustained
through to 48 weeks, and achievement of CD4 cell
count/percent above level of immune suppression for
age. The children were classified into treatment out-
come groups: virological and immunological success
(VS/IS), virological success and immunological failure
(VS/IF), virological failure and immunological success
(VF/IS) and both virological and immunological failure
(VF/IF). Mean WAZ and HAZ scores at the different
time points of follow up after HAART initiation were
compared using ANOVA and Scheffe’s multiple com-
parison test. Factors associated with treatment success
were analyzed using multinomial logistic regression and
presented as univariate and multivariate analyses. In
order to establish whether growth in children predicts
virological and immunological treatment outcome after
48 weeks of HAART we conducted a logistic regression
model for the different baseline z-scores and slope in
the first 24 weeks. In this model, we categorized virolo-
gical and immunological outcome as 1 (virological/
immunological success) and the other treatment out-
come groups as 0. The utility of the WAZ, HAZ or
growth velocity as predictors of successful treatment
outcome was determined by calculating the sensitivity,
specificity and ROC curves. Generalized estimating
equations (GEE) were used to analyze weight and height
velocity for different age groups during the 48 weeks of
follow-up adjusting for various baseline factors. All sta-
tistical analyses were assessed for statistical significance
at the p < 0.05 alpha level. All statistical analyses were
performed using STATA Version10 (Copyright 1984-
2007 Statistics/Data Analysis StataCorp 4905 Lakeway
Drive, College Station, TX 77845 USA).
Results
Study population
The baseline characteristics of the 124 HIV infected
children enrolled into the study and initiated on
HAART are presented in Table 1. The median age was
5.0 years (IQR 2.1 -7.0) and 49% (61/124) were female.
Only six (4%) children were below 12 months of age
and the majority, 65% (80/124) were over 3 years of age.
The children were more likely to be stunted than wasted
with a median HAZ of -2.0 (IQR -2.9, -1.2) and WAZ of
-1.2 (IQR -2.1, - 0.5) at baseline. The median CD4 cell
percent and log10 HIV RNA were 11.75% (IQR 7.5 -
18.0) and 5.55 (5.2 - 5.8) copies/ml respectively. All the
children were ART naïve at enrollment and 95% (123/
130) completed 48 weeks of follow up. Seven children
died during the study follow up; the causes of death
included presumed pneumocystis carinii pneumonia,
cerebral toxoplasmosis, HIV nephropathy, severe anae-
mia and diarrhoea. None of the deaths were related to
the antiretroviral drugs. All the children were on their
initial HAART regimen at the end of the 48 weeks.
After HAART initiation the children had fewer sick vis-
its during weeks 24 - 48 when compared to the initial
24 weeks on therapy (data not shown). On the basis of
treatment outcome there were 80 (65%) VS/IS, 27 (22%)
VS/IF, 10 (8%) VF/IS and 7 (5%) VF/IF children, in the
respective groups [Table 1]. The baseline characteristics
of each group were similar except for their baseline; age,
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The VF/IS treatment outcome category were the young-
est with a median age of 1.7 years (IQR 0.9-2.8) and had
the highest median viral load of 5.88 copies/ml (IQR 5.7
- 5.9). The immunological failure groups (VS/IF and
VF/IF) both had baseline median CD4 cell percent
below 10% at study entry and they were significantly dif-
ferent from the immunological success groups (VS/IS &
VF/IS) (p = 0.0001).
Changes in growth parameters of children on HAART
according to treatment outcome group
Mean changes in WAZ and HAZ scores during the 48
weeks of HAART therapy by treatment outcome groups
are presented in Figure 1. The BMI z scores did not
change significantly over the follow up period. There
were no statistically significant differences in BMI z
scores between the treatment failures and the treatment
s u c c e s sg r o u p sa ta n yo ft h et i m ep o i n t s( d a t an o t
shown). By the end of the study all the treatment out-
come groups had a significant increase in mean growth
z scores regardless of their virological and immunologi-
cal treatment outcome. The overall mean WAZ and
HAZ scores increased from -1.14 (SD) and -2.06 (SD) at
baseline to + 0.6 (SD) and -0.41 (SD) respectively by 48
weeks (p = 0.001).
The VS/IS and VF/IS groups both had significant
improvements in mean HAZ and WAZ scores on
Table 1 Baseline characteristics of the children according to antiretroviral treatment outcome group
Characteristic All VS/IS** VS/IF VF/IS VF/IF P
Number (%) 124 80 (65) 27 (22) 10 (8) 7 (5)
Sex n(%)
Male 63 (51) 40 (50) 13 (48) 5 (50) 5 (71)
Female 61 (49) 40 (50) 14 (52) 5 (50) 2 (29) 0.73†
Age (years)
median (IQR) 5.0 (2.1- 7.0) 4.7 (2.0 -8.6) 7.0 (5.4-9.8) 1.7 (0.9 - 2.8) 4.08(1.3 -6.6) 0.0001*
a
BAZ¥
Median (IQR) 0.29 (-2.9, -1.2) 0.42 (-0.8, 0.9) -0.42 (-1.7, 0.4) 0.44 (0.2, 1.3) 0.37 (0.3, 1.0) 0.01*
a
WAZ¥
median (IQR)‡ -1.2 (-2.1, - 0.5) -1.13 (-1.9, - 0.2) -2.10 (-2.9,-1.2) -1.33 (-2.1, -0.6) -0.90 (-1.1, -0.6) 0.06
a
HAZ¥
median (IQR) -2.0 (-2.9, -1.2) -1.95 (-2.6, -1.1) -2.39 (-3.2, -1.42) - 2.55 (-3.7, -1.3) -1.99 (-3.2, -1.5) 0.18
a
#WHO stage n (%)
Stage1 23 (19) 14(18) 6 (22) 2 (20) 1(14)
Stage 2 63 (51) 37(46) 17 (63) 5 (50) 4(57)
Stage 3 38 (30) 29(36) 4 (15) 3 (30) 2(29) 0.61
WAZ category‡
WAZ >-2 81 (72) 58 (77) 10 (48) 7 (70) 6 (100)
WAZ <=-2 31 (28) 17 (23) 11 (52) 3 (30) 0 (0) 0.02*
HAZ category
HAZ >-2 62 (50) 42 (53) 12 (44) 4 (40) 4 (57)
HAZ <=-2 62 (50) 38 (47) 15 (55) 6 (60) 3 (43) 0.78
BAZ category
BAZ >-2 117 (94) 75 (94) 25 (93) 10 (100) 7(100)
BAZ <=-2 7 (6) 5 (6) 2 (7) 0 (0) 0 (0) 0. 75
Log10 HIV-1 RNA
median (IQR) 5.55 (5.2 - 5.8) 5.54 (5.2 - 5.9) 5.36 (4.9 - 5.7) 5.88 (5.7 - 5.9) 5.76 (5.6 - 6.2) 0.007*
a
CD4 cell %
median (IQR)§ 11.75 (7.5 - 18.0) 14.7 (10.3 -19.7) 7.2 (3.3 - 9.0) 14.6 (8.4 - 21.0) 5 (3.8 -11.1) 0.0001*
a
CD4 cell % category
n (%)
≤ 5% 19 (16) 6 (8) 8 (31) 1 (10) 4 (57)
>5 %-≤ 10% 30 (25) 13 (17) 13 (50) 3 (30) 1 (14)
> 10% 71 (59) 58 (75) 5 (19) 6 (60) 2 (29) < .0001*
a Kruskal Wallis tests for p values and others based on Pearson Chi-squared test *Statistically significant at the 0.05 alpha level ‡n = 112 because 12 children >10
yrs #according to WHO paediatric clinical staging 2003 §4 missing CD4 cell percents at baseline. ¥BAZ = basal metabolic rate z score, ¥WAZ = weight for age z
score, ¥HAZ = height for age z score. **VS = virological success, IS = immunological success, VF = virological failure, IF = immunological failure.
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not a requirement for an initial increase in weight and
height (Figure 1). The VF/IS category (which comprised
of comparatively younger children) had a more robust
increase in mean growth z scores with a WAZ increas-
i n gf r o m-0 . 9 8( S D1 . 7 )t o+1 . 2 2( S D1 . 5 )a n dH A Z
from - 1.99 (SD1.7) to 0.76 (SD 2.4) (Table 2 and 3).
Unlike the other treatment outcome groups, the VS/IF
group had a slow and modest increase in HAZ and did
not achieve a mean HAZ of 0 by the end of the 48
week follow up (Figure 1). The VF/IF group had greater
than 1 SD unit increase in WAZ and HAZ, without
complete suppression of virus or restoration of CD4
cells. However, this small group (n = 7) experienced a
log drop in median viral load (mean 5.8 to 4.8) and a
significant increase in median CD4 cell percent (5.0 to
17.4) between baseline and 48 weeks.
When the treatment outcome groups were categorized
by age, the VS/IF and VF/IF groups did not include any
children less than one year of age, indicating than none
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Figure 1 Mean WAZ (left)a n dH A Z ( right) scores from baseline to 48 weeks in the VS/IS treatment outcome group according to age
category.
Table 2 Mean WAZ values at baseline and 24 and 48 weeks after HAART initiation
Treatment Outcome group Baseline(O) WAZ values 24 wks 48 wks P
VS/IS (n = 75)#
WAZ mean (SD) -1.07 (1.3) -0.05 (1.4) 0.50 (1.2) < 0.0001*
VS/IF (n = 21)
WAZ mean (SD) -1.84 (1.3) -1.02 (1.3) - 0.41 (1.2) 0.002
VF/IS (n = 10)
WAZ mean(SD) -0.98 (1.7) 0.44 (1.5) 1.22 (1.5) 0.013
VF/IF (n = 6)
WAZ mean (SD) -0.70 (0.63) 0.37 (0.76) 0.97 (0.8) 0.004
†12 missing WAZ values were > 10 yrs *ANOVA, statistically significant at the 0.05 alpha level. #n = 75, 71 & 69 at 0, 24 and 48 weeks respectively. WAZ =
Weight for Age z score. VS = virological success, VF = virological failure, VF = virological failure and IF = immunological failure.
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48 weeks on HAART [Figure 2, 4]. All children had a
significant mean increase in WAZ and HAZ but the 1-3
year olds (p < 0.0001) and the > 3 year olds (p < 0.0001)
had a less robust increase in WAZ and HAZ when com-
pared to infants <1 year of age [Figure 1, 4].
Factors associated with treatment outcomes
When the baseline characteristics were placed into a
univariate model for association with the successful
treatment outcome group (VS/IS) compared to the
other treatment outcome groups combined, only CD4
cell % at baseline was significantly associated with suc-
cessful treatment outcome [Table 4]. The children with
CD4 cells > 10% at HAART initiation were seven times
more likely to have a successful treatment outcome (VS/
IS) when compared to those children with a CD4 cell
percent < 10%. The other factors, including age, sex,
HIV RNA, WAZ and HAZ were not significantly asso-
ciated with successful treatment outcome. In a multi-
variate model age and WHO clinical stage were also
associated with successful treatment outcome after
Table 3 Mean HAZ values at baseline and 24 and 48 weeks after HAART initiation
Treatment Outcome group Baseline(0) HAZ values 24 wks 48 wks P
VS/IS (n = 80)
HAZ mean (SD) -1.95 (1.4) -0.88 (1.9) 0.005 (1.8) < 0.0001*
VS/IF (n = 27)
HAZ mean (SD) -2.25 (1.2) -1.88 (1.2) - 1.16 (1.3) 0.005
VF/IS (n = 10)
HAZ mean(SD) -1.99 (1.7) - 0.76 (1.5) 0.59 (2.4) 0.031
VF/IF (n = 7)
HAZ mean (SD) - 2.03 (1.3) -1.13 (1.0) - 0.07 (1.1) 0.018
*ANOVA, statistically significant at the 0.05 alpha level. # n = 80, 75 & 73 at 0, 24 and 48 weeks respectively. HAZ = Height for age z score. VS = virological
success, VF = virological failure, VF = virological failure and IF = immunological failure.
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Page 7 of 11adjusting for sex, HIV RNA, CD4 cell %, WAZ and
HAZ [Table 4]. The mean HAZ and WAZ slopes from
baseline to 48 weeks were indicatively similar in all the
groups except for the VS/IF group, which was older,
where the slopes for WAZ and HAZ were much less
than the other treatment outcome groups [Figure 2].
Weight and height velocity were not significantly asso-
ciated with treatment outcome when age, baseline CD4
cell % and WHO clinical stage were included in the
GEE model.
In a multinomial logistic regression, older age >18
months (p < 0.001), lower (<10%) baseline CD4 cell %
(p = 0.001) and lower (<-2 SD) baseline HAZ (p <
0.001) were significantly associated with immunological
failure alone (VS/IF), while lower age < 18 months (p =
0.027) was associated with virological failure alone (VF/
IS); and lower CD4 cell % (p = 0.014) was associated
with an observation of a both a virological and immuno-
logical failure(VF/IF) at 48 weeks. Age had the greatest
predictive probability (44%) for observing both an
immunologic and virologic success.
Viral and immune response to HAART according to
treatment outcome groups
Eighty six percent (107/124) of the children had unde-
tectable viral load (< 400 copies/ml) and 73% (90/124)
had immune restoration after 48 weeks of HAART. The
proportion of children less than one year, one to three
years and over three years of age with VS at 48 weeks
were 50% (3/6), 82% (34/38) and 90% (68/73) respec-
tively. The proportion of children with immunological
success (IS) in the same age groups were 83% (5/6), 97%
(37/38) and 89% (65/73) respectively. The one child
under one year of age (1/6) who did not achieve immu-
nological success at 48 weeks had a CD4 cell percent of
24%. The mean CD4 cell percent after 48 weeks of
HAART was significantly different for the 4 categories:
32.4% (SD 7.0) in the VS/IS, 18% (SD 4.9) in the VS/IF,
32.2% (SD 4.9) in the VF/IS, 17.5% (SD 4.5) in the VF/
IF group (p < 0.001). Twenty four weeks after HAART
initiation, the mean log10 HIV RNA in the VS/IS, VS/
IF, VF/IS and VF/IF was also different: 2.6 (SD 0.37), 2.7
(SD 0.13), 4.0 (SD 0.80) and 4.8 (SD 0.79) respectively
(p < 0.01). By definition, all the children in the VS/IS
and VS/IF groups had HIV-1 RNA < 400 copies/ml at
24, 36 and 48 weeks on HAART; none of the children
in the VF/IS and VF/IF groups had a viral load < 400
copies/ml at the same time points.
Utility of growth parameters for predicting successful
treatment outcomes
Used by themselves, the baseline WAZ, HAZ and 24
week WAZ and HAZ, and first 24 week WAZ and HAZ
velocity showed modest to low sensitivity (< 63%) and
specificity (< 42%) (data not shown) for predicting suc-
cessful treatment outcome. However, when they were
used together in a model to predict success or failure at
a cut-off of model probability >0.5, there was increased
sensitivity of 87.3%, but very low specificity of 27.0%.
Discussion
Similar to other studies from Africa and other resource
limited settings, HIV infected children in this study
experienced a significant increase in height and weight
after initiation of NNRTI based HAART [18-24]. The
younger VF/IS group experienced a robust growth
response despite failing to completely suppress virus on
therapy. Our findings are similar to those of Ghaffari et
al who found that the children on HAART with immu-
nological treatment success, and with or without com-
plete viral suppression had similar increases in weight
and height z scores at 48 and 96 weeks post therapy
[25]. The authors postulate that although the virus may
still replicate post therapy, its effect on growth may be
less deleterious. Our study findings concur with the
above observation and suggests that complete viral sup-
pression may not be a requirement for the initial growth
response in children on HAART [26] as long as there is
a robust immune response. Children have high lympho-
proliferative responses compared to adults which may
help explain these findings. In contrast, Verweel et al
found that the children on HAART who were viral
responders had significant increases in height and
weight while the non responders did not [13]. Guillen et
al also found that children with complete viral suppres-
sion had more significant increases in height and weight
when compared to children with inadequate viral
Table 4 Baseline factors associated with successful
treatment outcome (VS/IS)
Baseline characteristic Unadjusted OR (95%
CI)
Adjusted OR (95%
CI) †
Age
> 18 months (vs < 18
mths)
1.07 (0.39 - 2.96) 4.6 (1.14 -19.1)*
Sex
Male (vs Female)
0.91 (0.44 - 1.91) 0.71 (0.27 - 1.85)
CD4 cell %
>10% (vs ≤ 10%)
7.04 (3.07 - 16.19)** 6.97 (2.6 - 18.6)**
HIV-1 RNA (copies/ml)
< 750,000 (vs ≥ 750,000)
1.95 (0.51 - 7.51) 1.42 (0.29 - 6.98)
WHO stage
1&2 (vs 3)
2.21 (0.93 - 5.24) 3.50 (1.05 - 12.7)*
WAZ
≤ -2 (vs ≥ -2)
0.48 (0.20 -1.13) 0.50 (0.14 -1.78)
HAZ
≤ -2 (vs > -2)
0.79 (0.38 - 1.66) 1.19 (0.39 - 3.65)
†Adjusted for age, sex, CD4 cell %, viral load, WHO stage, WAZ and HAZ. **p
< 0.0001 *p = < 0.05. HAZ = Height for age z score, WAZ = weight for age z
score and WHO = World Health Organization.
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Page 8 of 11suppression [27]. The differences noted in these two
studies could be related to their small sample size, older
age of the children, longer follow up period, or due to
most of their study children being on second line ther-
apy at the time of evaluation. In comparison, our cohort
were all ART naïve, had a high rate of adherence to the
antiretroviral fixed dose combination and the VF/IF
group also had an initial modest response to therapy.
However, other studies have also documented the signif-
icant increase in growth velocity while on HAART,
without complete viral suppression [2,10,26]. Similar to
our findings these studies also found no significant
change in BMI on therapy and suggest that unlike adults
children on therapy increase in both height and weight
and therefore maintain the same BMI.
Older infected children in resource limited settings are
usually long term survivors with severe immunosuppres-
sion and are less likely to have a rapid increase in height
on HAART [26]. In our study, the older VS/IF group
had the poorest growth response to HAART suggesting
that immune reconstitution may be more critical than
complete viral suppression for initial growth response in
children [25]. When compared to the other treatment
outcome groups in the study, these children had a
higher baseline viral load, were more severely immuno-
suppressed and wasted and their growth response to
therapy was modest. A longer follow-up may have pro-
vided more information on their potential for catch-up
growth. However, considering findings from other stu-
dies with longer follow up, increases in height are less
pronounced when HAART is initiated later [26,28].
Therefore, to ensure that HIV infected children reach
their full height potential, HAART needs to be initiated
early before irreversible stunting occurs. This requires
early identification of HIV infected children and could
be achieved through scale up of national early infant
HIV diagnosis (EID) programs using dried blood spots
(DBS)[29]. From our data, children who were not show-
ing a significant increase in height or weight were also
failing immunologically. Another study found that
height growth velocity was a predictor of survival inde-
pendent of viral load, age and CD4 cell count in HIV
infected children on HAART [2]. In our cohort weight
and height velocity over the 48 weeks did not predict
virologic or immunologic treatment outcome. This may
be related to the initial drop in viral load and modest
increase in CD4 cell percent in most children leading to
an initial growth response.
The children who initiated HAART with a low CD4
cell percent, regardless of age were less likely to have a
robust increase in CD4 cells. It seems these children, in
fact have lost their potential for ‘good enough’ immuno-
logical reconstitution and therefore they do not reach
our threshold for ‘immunological success’ within the
first 48 weeks on therapy. These findings are consistent
with other studies where delay in initiation of HAART
is more likely to lead to treatment failure in children
and adults [19,20,28]. Our study further emphasize the
importance of initiating HAART early in children so as
to suppress virus, restore immune function and enable
satisfactory somatic growth. It is critical to ensure that
these initial growth responses in children from sub-
Saharan Africa are sustained beyond the early years of
therapy. Longer term follow up of children on HAART
from Thailand, report younger age, higher baseline CD4
cell % and sustained viral suppression after 24 weeks as
predictors of immune recovery at week 96 [28]. In addi-
tion, a study from Cote d’Ivoire reported improved sur-
vival and sustained viral suppression with good immune
recovery in children on HAART for a median follow up
of 36 months [30].
Our documentation of early growth responses on
HAART, despite inadequate viral suppression in children
from a resource limited setting is encouraging. However,
the continued replication of virus on HAART leads to
selection of resistant mutations which may limit future
treatment options [20,31,32]. Children in resource lim-
ited settings have even more limited treatment options
and remaining on a first line regimen with adequate
immune recovery and adequate growth response may be
more important than switching to second line therapy to
ensure complete viral suppression [25]. Therefore it is
important to develop strategies that ensure good adher-
ence to the first line regimen and close clinical monitor-
ing may be the better option for scaling up ART and
improving survival of HIV infected children from
resource limited settings. In the larger Ugandan popula-
tion similar robust growth responses may not occur in all
children initiating HAART because of the varying infec-
tious diseases and socio-economic factors in the home.
There were certain limitations to our study including
the small number of children in the failure groups and
the lack of growth data for HIV negative control chil-
dren which may have affected the results. Also, the fol-
low-up duration was 48 weeks so we were unable to
assess the long term impact of HAART on growth,
despite inadequate viral suppression. However, the
strength of this study is that it was a prospective cohort
with longitudinal clinical and laboratory data collected
consistently with no child lost to follow up, except for
those who died. In addition, the children had high
adherence levels to HAART and the majority experi-
enced viral and immune treatment success with asso-
ciated improvement in growth. Larger studies with
longer follow up on therapy would be beneficial in doc-
umenting the sustained growth response of infected
children and guiding future treatment strategies for chil-
dren from resource limited settings.
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In a cohort of HIV infected Uganda children we demon-
strated a significant increase in weight and height during
treatment with HAART. The age at initiation of
HAART determined the magnitude of the growth
response with the more significant increases in weight
and height response documented in the youngest age
group (<1 year). Of note, those children who did not
experience complete viral suppression on therapy but
did show immunologic success also showed a marked
improvement in growth parameters. Children who
initiated therapy with severe immune suppression were
less likely to restore immune function and only had
modest growth response. These data emphasize the
importance of initiating HAART early to ensure ade-
quate immune and growth responses.
Acknowledgements
The authors would like to thank the families and children who participated
in the International leadership Award (ILA) study. Their commitment to this
important study has advanced our knowledge and understanding of
antiretroviral treatment for HIV infected children from resource limited
settings. This study could not have been done without the dedication of the
ILA study staff based at Makerere University -Johns Hopkins University
research collaboration and the support of the Elizabeth Glaser Pediatric AIDS
Foundation (EGPAF) through the ILA grant. We thank Prof. Peter Mugyenyi
(JCRC Kampala Uganda) and Prof. Mark Kline (Baylor College of Medicine,
Houston TX) for providing consultation to the ILA program and study.
Author details
1Department of Paediatrics and Child Health, Makerere University, Kampala,
Uganda.
2Makerere University-Johns Hopkins University Research
Collaboration, Kampala, Uganda.
3School of Public Health, Makerere
University, Kampala, Uganda.
4Center for International Health, University of
Bergen, Norway.
5Johns Hopkins University, Baltimore MD, USA.
Authors’ contributions
PM contributed to the statistical analysis and writing of the manuscript, LBM
contributed to the conduct of the study (study coordinator), collection of
data, analysis and writing of the manuscript, PA contributed to collection of
data and analysis, DB (senior statistician) contributed to study design,
statistical analysis, data interpretation and writing of the manuscript, MM
contributed to the statistical analysis and interpretation, TT contributed to
the analysis, review and writing of the manuscript. MGF contributed to the
writing and review of manuscript. PMM(principal investigator) corresponding
author, contributed to the study design and conduct, analysis and writing of
the manuscript. All authors read and approved the manuscript and agreed to
the submission.
Competing interests
The authors declare that they have no competing interests.
Received: 24 March 2010 Accepted: 6 August 2010
Published: 6 August 2010
References
1. Berhane R, Bagenda D, Marum L, Aceng E, Ndugwa C, Bosch RJ, Olness K:
Growth failure as a prognostic indicator of mortality in pediatric HIV
infection. Pediatrics 1997, 100(1):E7..
2. Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RE Jr: Growth, survival
and viral load in symptomatic childhood human immunodeficiency
virus infection. Pediatr Infect Dis J 2003, 22(12):1033-1039.
3. Fergusson P, Tomkins A: HIV prevalence and mortality among children
undergoing treatment for severe acute malnutrition in sub-Saharan
Africa: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg
2009, 103(6):541-548.
4. Arpadi SM: Growth failure in children with HIV infection. J Acquir Immune
Defic Syndr 2000, 25(Suppl 1):S37-42.
5. Miller TL: Nutritional aspects of HIV-infected children receiving highly
active antiretroviral therapy. AIDS 2003, 17(Suppl 1):S130-140.
6. Arpadi SM, Cuff PA, Kotler DP, Wang J, Bamji M, Lange M, Pierson RN,
Matthews DE: Growth velocity, fat-free mass and energy intake are
inversely related to viral load in HIV-infected children. J Nutr 2000,
130(10):2498-2502.
7. World Health Statistics 2009. World Health Organization Geneva
Switzerland 2009.
8. Uganda Demographic and Health Survey 2006. Calverton, Maryland,
USA: UBOS and Macro International Inc.; 2007.
9. De Beaudrap P, Rouet F, Fassinou P, Kouakoussui A, Mercier S, Ecochard R,
Msellati P: CD4 cell response before and after HAART initiation according
to viral load and growth indicators in HIV-1-infected children in Abidjan,
Cote d’Ivoire. J Acquir Immune Defic Syndr 2008, 49(1):70-76.
10. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW: Growth
in HIV-infected children receiving antiretroviral therapy at a pediatric
infectious diseases clinic in Uganda. AIDS Patient Care STDS 2008,
22(3):245-251.
11. Kekitiinwa A, Lee KJ, Walker AS, Maganda A, Doerholt K, Kitaka SB,
Asiimwe A, Judd A, Musoke P, Gibb DM: Differences in factors associated
with initial growth, CD4, and viral load responses to ART in HIV-infected
children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir
Immune Defic Syndr 2008, 49(4):384-392.
12. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ: Effectiveness of
antiretroviral therapy among HIV-infected children in sub-Saharan Africa.
Lancet Infect Dis 2008, 8(8):477-489.
13. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de
Groot R: Treatment with highly active antiretroviral therapy in human
immunodeficiency virus type 1-infected children is associated with a
sustained effect on growth. Pediatrics 2002, 109(2):E25..
14. Musoke PM, Barlow-Mosha L, Bagenda D, Mudiope P, Mubiru M, Ajuna P,
Tumwine JK, Fowler MG: Response to antiretroviral therapy in HIV
infected Ugandan children exposed and not exposed to single dose
Nevirapine at birth. J Acquir Immune Defic Syndr 2009, 52(5):560-568.
15. WHO: Scaling Up Antiretroviral Therapy in Resource-Limited Settings:
Guidelines for a Public Health Approach. Geneva, Switzerland: World
Health Organization 2002.
16. Barlow-Mosha L, Ajuna P, Lutajjumwa M, Mubiru M, Musoke P: Early
effectiveness of triomune in HIV infected children. IAS Conference Rio de
Janeiro, Brazil, 24-27 July 2005 Abstract WeOa0103 .
17. WHO: Anrtho and WHOAnrthroPlus. version 3, April 2009 soft ware 2009
[http://www.who.int/childgrowth/software/en].
18. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM,
Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, et al: Clinical
outcomes and CD4 cell response in children receiving antiretroviral
therapy at primary health care facilities in Zambia. JAMA 2007,
298(16):1888-1899.
19. Essajee SM, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, Hoover W,
Lawrence R, Spiegel H, Pollack H, et al: Immunologic and virologic
responses to HAART in severely immunocompromised HIV-1-infected
children. AIDS 1999, 13(18):2523-2532.
20. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F,
Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, et al:
Predictors of long-term viral failure among Ugandan children and adults
treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007,
46(2):187-193.
21. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ,
Mntambo M, Thomas M, Nixon K, et al: Preliminary outcomes of a
paediatric highly active antiretroviral therapy cohort from KwaZulu-
Natal, South Africa. BMC Pediatr 2007, 7:13.
22. Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA,
Richardson BA, Overbaugh J, Emery S, Wariua G, Gichuhi C, et al: Early
response to highly active antiretroviral therapy in HIV-1-infected Kenyan
children. J Acquir Immune Defic Syndr 2007, 45(3):311-317.
23. Banerjee T, Pensi T, Banerjee D, et al: Impact of HAART on survival, weight
gain and resting energy expenditure in HIV-1-infected children in India.
Ann Trop Paediatr 2010, 30(1):27-37.
Musoke et al. BMC Pediatrics 2010, 10:56
http://www.biomedcentral.com/1471-2431/10/56
Page 10 of 1124. Pierre RB, Steel-Duncan JC, Evans-Gilbert , et al: Effectiveness of
antiretroviral therapy in treating paediatric HIV/AIDS in Jamaica. West
Indian Med J 2008, 57(3):223-230.
25. Ghaffari G, Passalacqua DJ, Caicedo JL, Goodenow MM, Sleasman JW: Two-
year clinical and immune outcomes in human immunodeficiency virus-
infected children who reconstitute CD4 T cells without control of viral
replication after combination antiretroviral therapy. Pediatrics 2004,
114(5):e604-611.
26. Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA,
Wiznia AA: Growth of human immunodeficiency virus-infected children
receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005,
24(4):352-357.
27. Guillen S, Ramos JT, Resino R, Bellon JM, Munoz MA: Impact on weight
and height with the use of HAART in HIV-infected children. Pediatr Infect
Dis J 2007, 26(4):334-338.
28. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P,
Sirisanthana V: Pattern and predictors of immunologic recovery in
human immunodeficiency virus-infected children receiving non-
nucleoside reverse transcriptase inhibitor-based highly active
antiretroviral therapy. Pediatr Infect Dis J 2009, 28(6):488-492.
29. Sherman CG, Stevens G, Jones SA, et al: Dried blood spots improve access
to HIV diagnosis and care for infants in low-resource settings. J Acquir
Immune Defic Syndr 2005, 38(5):615-617.
30. Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C,
Blanche S, Msellati P: Long-term survival and immuno-virological
response of African HIV-1-infected children to highly active antiretroviral
therapy regimens. AIDS 2006, 20(18):2315-2319.
31. Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F,
Rouzioux C, Blanche S: Prevalence and risk factors associated with
antiretroviral resistance in HIV-1-infected children. J Med Virol 2007,
79(9):1261-1269.
32. Pillay D: The emergence and epidemiology of resistance in the
nucleoside-experienced HIV-infected population. Antivir Ther 2001,
6(Suppl 3):15-24.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2431/10/56/prepub
doi:10.1186/1471-2431-10-56
Cite this article as: Musoke et al.: Growth, immune and viral responses
in HIV infected African children receiving highly active antiretroviral
therapy: a prospective cohort study. BMC Pediatrics 2010 10:56.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Musoke et al. BMC Pediatrics 2010, 10:56
http://www.biomedcentral.com/1471-2431/10/56
Page 11 of 11